혈액학 분야 제휴 및 라이선싱 계약(2016-2026년)

Understand the hematology partnering landscape using intelligence from 234 real-world collaboration and licensing deals.

Hematology Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 234 partnering deals involving hematology assets, technologies and development programs.

Hematology partnering spans both malignant and non-malignant disorders and encompasses a diverse range of therapeutic approaches, technologies and stages of development. Deal structures reflect the scientific complexity of the field, the increasing use of targeted and advanced therapeutic approaches, and differing development and commercialization strategies across individual indications.

The report brings this activity together in one resource, enabling users to understand who is partnering, which hematology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in hematology partnering.

Understand the hematology partnering landscape

The report analyzes hematology dealmaking from 2016 to 2026, including:

• Trends in hematology partnering by year
• Deal activity by deal type
• Industry sector
• Stage of development at the time of partnering
• Technology type
• Therapeutic indication
• Most active hematology dealmakers
• Leading deals by disclosed value
• How hematology partnering activity is evolving
• This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
• Benchmark hematology deal financials
• Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

• Headline deal values
• Upfront payments
• Milestone payments
• Royalty rates
• Users can investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
• This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
• Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
• Identify leading hematology dealmakers and prospective partners
• The report identifies the most active companies in hematology partnering and provides transaction histories that enable users to investigate their previous activity.

This can help users identify:

• Companies actively seeking hematology opportunities
• Prospective licensing and collaboration partners
• Organizations repeatedly partnering in relevant hematology indications
• Companies active at relevant stages of development
• Dealmakers demonstrating interest in particular technologies or therapeutic approaches
• Competitors pursuing related external innovation strategies
• For companies seeking to partner a hematology asset or technology, previous transaction activity can provide useful evidence of which organizations have demonstrated an appetite for comparable opportunities.
• Compare partnering activity across hematology indications and targets
• Hematology covers a range of malignant and non-malignant disorders with differing scientific, clinical and commercial dynamics.
• The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad hematology benchmarks and focus on transactions most relevant to a particular program or strategic interest.
• Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
• Understand how hematology agreements are structured
• The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

• Rights granted and retained
• Research and development responsibilities
• Licensing rights
• Exclusivity
• Geographic rights
• Intellectual property
• Development and regulatory obligations
• Manufacturing and supply responsibilities
• Commercialization rights
• Financial consideration
• Milestones and royalties
• Governance
• Term and termination provisions
• These real-world examples provide useful reference points when considering the appropriate structure for a hematology partnership.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying contract documents for selected hematology transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

• Scope of rights
• Development obligations
• Intellectual property
• Exclusivity
• Financial terms
• Milestone triggers
• Royalty provisions
• Commercialization rights
• Termination and other negotiated provisions
• For teams preparing or negotiating a hematology collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
• Comprehensive hematology deal directory
• The report includes a comprehensive directory of 234 hematology collaboration and licensing deals, providing a focused resource for identifying relevant precedent transactions.

Deals can be reviewed by:

• Company
• Technology type
• Therapeutic indication or target
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable hematology transactions, prospective partners and relevant deal structures.
• Search and Evaluation teams
• Understand which companies are actively seeking hematology opportunities across relevant indications, technologies and development stages.
• Biotechnology Companies Seeking Partners
• Identify organizations with demonstrated interest in comparable hematology assets and technologies.
• Corporate and R&D Strategy teams
• Understand how competitors and prospective partners are building hematology portfolios through external innovation.
• Competitive and Market Intelligence teams
• Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
• Legal and Transaction teams
• Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
• Turn market-wide hematology intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying hematology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in hematology dealmaking

• 2.1. Introduction
• 2.2. Hematology partnering over the years
• 2.3. Hematology partnering by deal type
• 2.4. Hematology partnering by industry sector
• 2.5. Hematology partnering by stage of development
• 2.6. Hematology partnering by technology type
• 2.7. Hematology partnering by therapeutic indication

Chapter 3 - Financial deal terms for hematology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for hematology partnering
• 3.3. Hematology partnering headline values
• 3.4. Hematology deal upfront payments
• 3.5. Hematology deal milestone payments
• 3.6. Hematology royalty rates

Chapter 4 - Leading hematology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in hematology partnering
• 4.3. List of most active dealmakers in hematology
• 4.4. Top hematology deals by value

Chapter 5 - Hematology contract document directory

• 5.1. Introduction
• 5.2. Hematology partnering deals where contract document available

Chapter 6 - Hematology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by hematology therapeutic target
• Deal directory
• Deal directory - Hematology deals by company A-Z
• Deal directory - Hematology deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Hematology partnering since 2016
• Figure 2: Hematology partnering by deal type since 2016
• Figure 3: Hematology partnering by industry sector since 2016
• Figure 4: Hematology partnering by stage of development since 2016
• Figure 5: Hematology partnering by technology type since 2016
• Figure 6: Hematology partnering by indication since 2016
• Figure 7: Hematology deals with a headline value
• Figure 8: Hematology deals with upfront payment values
• Figure 9: Hematology deals with milestone payment
• Figure 10: Hematology deals with royalty rates
• Figure 11: Active hematology dealmaking activity since 2016
• Figure 12: Top hematology deals by value since 2016